Shares of Dr Lal PathLabs Ltd rose 2.86% to ₹1,665 on Tuesday, extending gains for the fourth consecutive trading session. The stock has gained 6.01% over four sessions, 24.09% in the past three months, and 10.24% so far in 2026. According to Business Standard, investor sentiment remained positive after the diagnostics company announced on June 12 that it had incorporated a wholly owned subsidiary, DR LAL PATHLABS FZCO, in Dubai, United Arab Emirates. The stock was quoting 9% higher at ₹1,756.85 as of 11:34 AM, with average trading volumes jumping over five-fold as a combined 4.97 million shares changed hands on NSE and BSE.
Diagnostic services provider Dr Lal PathLabs Ltd announced the incorporation of its wholly owned subsidiary, DR LAL PATHLABS FZCO, in Dubai, United Arab Emirates on Friday, June 12, 2026. In an exchange filing, the company confirmed that the subsidiary was incorporated on June 12, 2026, with the company receiving the Certificate of Incorporation and licence from the Dubai Multi Commodities Centre (DMCC) authority. The company subscribed to the entire share capital of the subsidiary amounting to AED 19.135 million, divided into 19,135 shares of AED 1,000 each, giving it 100% ownership. The subsidiary will focus on strategic investments in diagnostics and allied healthcare activities, with the company exploring potential acquisitions, partnerships and joint ventures in the sector. The investment establishes a permanent physical and legal presence in the Middle East, with the subsidiary located in the Dubai Integrated Economic Zones (DIEZ) to benefit from tax efficiency and ease of doing business.
According to Business Standard, Dr Lal PathLabs achieved revenue of ₹703 crore in Q4 FY26 with 16.6% growth, primarily driven by growth in sample volumes. On a consolidated basis, the company posted a net profit of ₹132 crore in Q4 FY26, down 15.1% YoY. The company's EBITDA for Q4FY26 came in at ₹187 crore compared to ₹169 crore in Q4FY25, registering 10.5% growth with an EBITDA margin of 26.6%. The management indicated that the company is entering FY27 with strong operational momentum, a strengthened digital infrastructure, and a clear pathway towards sustaining early to mid-teens revenue growth. CareEdge Ratings expects the company's revenue to grow by 11-12% per annum in the near-to-medium term, with PBILDT margin expected to remain in the range of 26-29% in the medium term.
As reported by Business Standard, Dr Lal PathLabs continues to expand its presence in tier-3 and tier-4 cities through the franchise model, expecting to add around 1,000 patient service centres and around 20 pathology labs across the country to attract patient volume. The company also plans to add 5-7 imaging centres (capable for MRI, CT, Ultrasound and X-ray) per year, starting with northern and eastern parts of India. The company opened a new diagnostic centre 'Sovaaka' exclusively for preventive diagnostics, with the management indicating good initial response and plans to gradually expand these centres in the medium term based on overall response. This expansion aligns with the company's broader growth strategy in the Middle East region, with Dubai serving as a strategic hub for medical tourism and the large South Asian expat population.
According to CareEdge Ratings, the diagnostic industry is expected to witness stable double-digit revenue growth, ranging from 12-14%, driven by organic and inorganic expansion of players and paradigm shift in consumers towards preventive healthcare. Growth is supported by an increase in healthcare spending by ageing population, rising income levels, and rising awareness for preventive testing. As of March 31, 2026, Dr Lal PathLabs operated 312 clinical laboratories, 7,727 Patient Service Centers, and 13,935 Pick-up Points, serving individual patients, hospitals, healthcare providers, and corporate customers across India. The company's cost of diagnostic services in India is generally more affordable compared to many other countries, making India a fast emerging medical tourism hub with surge in patients from across the world.
